https://www.selleckchem.com/pr....oducts/vazegepant-hy
Apart from mantle cell lymphoma, where rituximab maintenance is generally accepted, post-auto HCT maintenance in other forms of NHL is less established. In patients who undergo allo HCT, the utilization of maintenance therapy is an important component of improving post-HCT outcomes, however, an individualized approach that considers patient factors such as residual toxicity from HCT, an immature graft with poor graft function, infection, and graft versus host disease create a complex environment for aggressive intervent
Curtir
Comentario
Compartilhar
